Sustainable Pharmaceutical Innovation for COVID-19 and Other Infectious Diseases

How to Best Enable Pharma Innovation Beyond the COVID-19 Crisis

Innovating in response to public health challenges like COVID-19 does not always align well with pharmaceutical industry commercial models or shareholder expectations. More sustainable and scalable ways of incentivizing innovation in response to infectious disease threats are needed.

Sonja Marjanovic @SonjaCambs, Carolina Feijao

A Stable Blood Supply Is Critical in the COVID-19 Era

Millions of lives depend on the U.S. blood supply. But no one knows exactly how much blood is in the system at any given time, or whether it's enough to meet demand. The federal government has no way to collect that data, and hospitals don't share it with each other. What can be done to strengthen the system?

It's Going to Be the Vaccination, Stupid!

The increasingly positive news on COVID-19 vaccine development is also bringing growing alarm over whether Americans will trust these vaccines when they become available. While we were clearly not prepared for this virus, we now need to understand how we are going to roll out any proven vaccine.

Robert H. Brook, John J. Rydzewski

Patients Should Have a Role in Deciding the Value of Medicines

Patients, their family members, and the general public have historically been excluded from contributing to health care value assessment models. But methods for including patient voices in research are far less complicated or demanding than some researchers believe they will be.

Thomas W. Concannon @tconcannon, Lori Frank @LoriBethFrank